FASEB SRC on The Growth Hormone/Prolactin Family in Biology and Disease

描述（由申请人提供）：“生长激素（GH）和催乳素（PRL）家族”定义了一个蛋白质家族，包括几个成员，包括GH、PRL、胎盘乳原（PLs）和各种称为血管抑制素的蛋白水解片段。这些蛋白处于人类病理生理学两个主要领域的交叉点：细胞因子受体（与它们共享多种分子机制）和（神经）内分泌学（在调节、分泌、功能和病理生理水平上与其他激素的多种联系）。在这两个领域，GH和PRL激素已经率先发现了从作用机制（例如，1992年第一个已知的细胞因子和受体复合物结构）到药物开发（Somavert， 2003年推出的第一个基于细胞因子核心的拮抗剂）的范式。现在很清楚，PRL和GH激素调节代谢（例如，β细胞质量，脂肪细胞分化，肌肉，葡萄糖稳态等），干细胞生物学，行为（例如，神经发生），癌症（几个器官），免疫反应等。这些新功能对科学界来说是非常令人兴奋的，包括该领域的基础、转化、临床和工业参与者。进一步的转化研究是必要的，以了解这些新功能的潜在机制，评估其实际临床影响，发现新的治疗适应症，开发靶向药物治疗和新的兴奋剂检测策略。因此，迫切需要通过组织一次定期和长期的会议，集中讨论这些问题，来聚集参与这些研究领域的日益扩大的社区。为此，申请人建立了一个新的FASEB SRC，题为“生物学和疾病中的生长激素和催乳素家族”。会议将涵盖多种领域，包括信号转导、用于识别GH和PRL在健康和疾病中的新生理功能的新型动物模型的发展、GH和PRL激素调节的新功能/组织、GH和PRL作用的生物信息学分析、新的药物靶点和临床前研究。最后，申请人将通过从提交的摘要中选择简短的演讲（只要符合我们的质量标准），确保涵盖最新的新发现和目前未包括在完整演讲中的相关主题。将作出重大努力吸引年轻研究者（资助、简短演讲、海报）。

DESCRIPTION (provided by applicant): The "Growth hormone (GH) and prolactin (PRL) family" defines a protein family that includes several members, including GH, PRL, placental lactogens (PLs) and various proteolytic fragments called vasoinhibins. These proteins are at the crossroads of two major fields in human pathophysiology: cytokine receptors (with whom they share multiple molecular mechanisms), and (neuro) endocrinology (multiple connections with other hormones at the regulation, secretion, functional and pathophysiology levels). In both areas, GH and PRL hormones have pioneered the discovery of paradigms, ranging from mechanisms of action (e.g., first known structure of cytokine and receptor complex in 1992) to drug development (Somavert, the first cytokine core-based antagonist launched in 2003). It is now clear that PRL and GH hormones regulate metabolism (e.g., beta cell mass, adipocyte differentiation, muscle, glucose homeostasis, etc), stem cell biology, behavior (e.g., neurogenesis), cancer (several organs), immune responses, etc. These novel functions are very exciting to the scientific community, including basic, translational, clinical and industrial actor in the field. Further translational investigations are necessary to understand the underlying mechanisms of these novel functions to evaluate their actual clinical impact discover new therapeutic indications, develop targeted drug therapy, and novel strategies of doping detection. There is therefore a critical need to gather the broadening community involved in these fields of research by organizing a regular and long-live meeting focused on these issues. To that end, the applicants have established a novel FASEB SRC entitled "The Growth Hormone and Prolactin Family in Biology and Disease". The conference will cover such diverse areas as signaling, development of novel animal models for identifying new physiological functions for GH and PRL in health and disease, new functions/tissues regulated by GH and PRL hormones, biomics profiling of GH and PRL actions and new drug targets and pre-clinical studies. Finally, the applicants will ensure coverage of the latest new findings and relevant topics not currently included as full talks by selecting short talks from abstracts that will be submitted (providing thy match our quality criteria). Major efforts to attract young investigators will be made (funding, short talks, posters).